CoChat

Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease

Open access
Mustaly-Kalimi, Sarah, Gallegos, Wacey, Marr, Robert A., Gilman-Sachs, Alice, Peterson, Daniel A., Sekler, Israel, Stutzmann, Grace E. · 2022 · Proceedings of the National Academy of Sciences

Published version of a preprint

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Abstract

Impairments in neural lysosomal- and autophagic-mediated degradation of cellular debris contribute to neuritic dystrophy and synaptic loss. While these are well-characterized features of neurodegenerative disorders such as Alzheimer’s disease (AD), the upstream cellular processes driving deficits in pathogenic protein mishandling are less understood. Using a series of fluorescent biosensors and optical imaging in model cells, AD mouse models and human neurons derived from AD patients, we reveal a previously undescribed cellular signaling cascade underlying protein mishandling mediated by intracellular calcium dysregulation, an early component of AD pathogenesis. Increased Ca 2+ release via the endoplasmic reticulum (ER)-resident ryanodine receptor (RyR) is associated with reduced expression of the lysosome proton pump vacuolar-ATPase (vATPase) subunits (V1B2 and V0a1), resulting in lysosome deacidification and disrupted proteolytic activity in AD mouse models and human-induced neurons (HiN). As a result of impaired lysosome digestive capacity, mature autophagosomes with hyperphosphorylated tau accumulated in AD murine neurons and AD HiN, exacerbating proteinopathy. Normalizing AD-associated aberrant RyR-Ca 2+ signaling with the negative allosteric modulator, dantrolene (Ryanodex), restored vATPase levels, lysosomal acidification and proteolytic activity, and autophagic clearance of intracellular protein aggregates in AD neurons. These results highlight that prior to overt AD histopathology or cognitive deficits, aberrant upstream Ca 2+ signaling disrupts lysosomal acidification and contributes to pathological accumulation of intracellular protein aggregates. Importantly, this is demonstrated in animal models of AD, and in human iPSC-derived neurons from AD patients. Furthermore, pharmacological suppression of RyR-Ca 2+ release rescued proteolytic function, revealing a target for therapeutic intervention that has demonstrated effects in clinically-relevant assays.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2211999119

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Decreased v-ATPase in AD mice are restored after normalizing intracellular Ca2+ levels. Hippocampus from 3–4-mo-old 3xTg-AD mice and age-matched NTg controls were immunolabeled for vATPase membrane-embedded V0a1 and cytosolic V1B2 subunits along with lysosomal surface marker (Lamp1). Representative high-resolution images of V0a1 (A) and V1B2 (B) were taken on Leica SP8 63X with 441X zoom of the primary cellular layer (PCL) and stratum radiatum (SR) of the CA1 field. Quantification showed decreased fluorescence density for (C) V0a1, (D) V1B2 in multiple regions of the hippocampus (CA1, CA3, DG) and cortex of 3xTg-AD mice, that was rescued with Ryanodex treatment (10mg/kg; 30-d i.p.). (E) There were no significant differences in Lamp1 density throughout the hippocampus and cortex. Colocalization of (F) V0a1 and (G) V1B2 to lysosomes specifies that deficits seen in vATPase are localized to lysosomes (NTg Vehicle, black bar, n = 8 animals; NTg Ryanodex, black pattern bar, n = 8 animals; 3xTg Vehicle, grey bar, n = 8 animals; 3xTg Ryanodex, grey pattern bar, n = 8 animals) *P <0.05
Fig. 1. Decreased v-ATPase in AD mice are restored after normalizing intracellular Ca2+ levels. Hippocampus from 3–4-mo-old 3xTg-AD mice and age-matched NTg controls were immunolabeled for vATPase membrane-embedded V0a1 and cytosolic V1B2 subunits along with lysosomal surface marker (Lamp1). Representative high-resolution images of V0a1 (A) and V1B2 (B) were taken on Leica SP8 63X with 441X zoom of the primary cellular layer (PCL) and stratum radiatum (SR) of the CA1 field. Quantification showed decreased fluorescence density for (C) V0a1, (D) V1B2 in multiple regions of the hippocampus (CA1, CA3, DG) and cortex of 3xTg-AD mice, that was rescued with Ryanodex treatment (10mg/kg; 30-d i.p.). (E) There were no significant differences in Lamp1 density throughout the hippocampus and cortex. Colocalization of (F) V0a1 and (G) V1B2 to lysosomes specifies that deficits seen in vATPase are localized to lysosomes (NTg Vehicle, black bar, n = 8 animals; NTg Ryanodex, black pattern bar, n = 8 animals; 3xTg Vehicle, grey bar, n = 8 animals; 3xTg Ryanodex, grey pattern bar, n = 8 animals) *P <0.05CC BY-NC-ND · PubMed Central
Fig. 2. Ryanodine receptor 2 (RyR2)-evoked Ca2+ release alkalizes lysosomal pH through v-ATPase proton pump interference in model cells. (A) Representative traces of RyR2-evoked Ca2+ release (10mM caffeine) on HEK293T cells overexpressing hippocampal-relevant RyR2 treated with control, Ryanodex or bafilomycin. (B) Cells were incubated with Fura-2AM and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n= 6 coverslips/treatment). Normalizing RyR2-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated RyR2-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR2-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran (n = 27 wells/treatment). (D–F) Representative traces overlaying RyR2-Ca2+ release and lysosomal pH indicate immediate lysosomal pH fluctuations with a rise in intracellular Ca2+ levels. (C and D) RyR2-evoked Ca2+ release alkalized lysosomal pH. (C and E) Normalizing RyR2-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated the RyR2-mediated lysosomal alkalization. (C and F) Inhibiting vATPase with bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR2-evoked Ca2+ release. *P < 0.05
Fig. 2. Ryanodine receptor 2 (RyR2)-evoked Ca2+ release alkalizes lysosomal pH through v-ATPase proton pump interference in model cells. (A) Representative traces of RyR2-evoked Ca2+ release (10mM caffeine) on HEK293T cells overexpressing hippocampal-relevant RyR2 treated with control, Ryanodex or bafilomycin. (B) Cells were incubated with Fura-2AM and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n= 6 coverslips/treatment). Normalizing RyR2-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated RyR2-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR2-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran (n = 27 wells/treatment). (D–F) Representative traces overlaying RyR2-Ca2+ release and lysosomal pH indicate immediate lysosomal pH fluctuations with a rise in intracellular Ca2+ levels. (C and D) RyR2-evoked Ca2+ release alkalized lysosomal pH. (C and E) Normalizing RyR2-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated the RyR2-mediated lysosomal alkalization. (C and F) Inhibiting vATPase with bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR2-evoked Ca2+ release. *P < 0.05CC BY-NC-ND · PubMed Central
Fig. 3. Modulating RyR-Ca2+ release regulates lysosomal pH in primary hippocampal murine cultures. (A) Representative traces of RyR-evoked Ca2+ release (10mM caffeine) on 3xTg-AD and NTg hippocampal primary neuronal cultures (12–14d) treated with control, Ryanodex, or bafilomycin. (B) Neurons were incubated with Fura-2AM and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n= 19 coverslips/treatment). Normalizing RyR-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated RyR-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran on hippocampal primary neuronal culture (n = 8 coverslips/treatment). (C) Baseline lysosomal pH is increased in 3xTg-AD neurons as compared to NTg neurons. RyR-evoked Ca2+ release alkalized lysosomal pH in NTg neurons, while no further lysosomal pH changes occurred in 3xTg-AD neurons. Ryanodex treatment (10μM; 1h) attenuated the RyR-mediated lysosomal alkalization and restored baseline lysosomal pH in 3xTg-AD neurons. (D) Bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR-evoked Ca2+ release in NTg nor 3xTg-AD neurons. *P < 0.05
Fig. 3. Modulating RyR-Ca2+ release regulates lysosomal pH in primary hippocampal murine cultures. (A) Representative traces of RyR-evoked Ca2+ release (10mM caffeine) on 3xTg-AD and NTg hippocampal primary neuronal cultures (12–14d) treated with control, Ryanodex, or bafilomycin. (B) Neurons were incubated with Fura-2AM and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n= 19 coverslips/treatment). Normalizing RyR-Ca2+ release with Ryanodex treatment (10μM; 1h) attenuated RyR-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran on hippocampal primary neuronal culture (n = 8 coverslips/treatment). (C) Baseline lysosomal pH is increased in 3xTg-AD neurons as compared to NTg neurons. RyR-evoked Ca2+ release alkalized lysosomal pH in NTg neurons, while no further lysosomal pH changes occurred in 3xTg-AD neurons. Ryanodex treatment (10μM; 1h) attenuated the RyR-mediated lysosomal alkalization and restored baseline lysosomal pH in 3xTg-AD neurons. (D) Bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR-evoked Ca2+ release in NTg nor 3xTg-AD neurons. *P < 0.05CC BY-NC-ND · PubMed Central
Fig. 4. Modulating RyR-Ca2+ regulates vATPase expression and lysosomal pH in HiN derived from AD and non-AD patients. HiN were immunolabeled for vATPase membrane-embedded V0a1 and cytosolic V1B2 subunits along with a lysosomal marker (LysoTracker). Representative images and quantification showed decreased fluorescence density for V0a1 (A, C; n = 9 coverslips/treatment), V1B2 (B, D; n = 9 coverslips/treatment), and LysoTracker (E; n = 14 coverslips/treatment), that was rescued with Ryanodex (10µM; 6h). (F) Representative traces of RyR-evoked Ca2+ release (10mM caffeine) on AD and non-AD HiN treated with control, Ryanodex (10µM; 1h), or bafilomycin (25nM; 4h). (G) Neurons were incubated with ratiometric indicator Fura-2AM, and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n = 8 coverslips/treatment). Normalizing RyR-Ca2+ release with Ryanodex treatment (10μM; 1h) decreased RyR-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran on HiN (n = 11 coverslips/treatment). (H) Baseline lysosomal pH is increased in AD HiN as compared to non-AD HiN. RyR-evoked Ca2+ release alkalized lysosomal pH in non-AD HiN, while no further pH changes occurred in AD HiN. Ryanodex treatment (10μM; 1h) attenuated the RyR-mediated lysosomal alkalization and restored baseline lysosomal pH in AD HiN. (I) Bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR-evoked Ca2+ release in non-AD nor AD HiN. *P < 0.05
Fig. 4. Modulating RyR-Ca2+ regulates vATPase expression and lysosomal pH in HiN derived from AD and non-AD patients. HiN were immunolabeled for vATPase membrane-embedded V0a1 and cytosolic V1B2 subunits along with a lysosomal marker (LysoTracker). Representative images and quantification showed decreased fluorescence density for V0a1 (A, C; n = 9 coverslips/treatment), V1B2 (B, D; n = 9 coverslips/treatment), and LysoTracker (E; n = 14 coverslips/treatment), that was rescued with Ryanodex (10µM; 6h). (F) Representative traces of RyR-evoked Ca2+ release (10mM caffeine) on AD and non-AD HiN treated with control, Ryanodex (10µM; 1h), or bafilomycin (25nM; 4h). (G) Neurons were incubated with ratiometric indicator Fura-2AM, and ER-Ca2+ release was measured as peak change in 340/380 ratio over baseline (n = 8 coverslips/treatment). Normalizing RyR-Ca2+ release with Ryanodex treatment (10μM; 1h) decreased RyR-evoked Ca2+ release. Inhibiting vATPase with bafilomycin (25nM; 4h) did not affect RyR-evoked Ca2+ release. Lysosomal pH was measured using LysoSensor Yellow/Blue dextran on HiN (n = 11 coverslips/treatment). (H) Baseline lysosomal pH is increased in AD HiN as compared to non-AD HiN. RyR-evoked Ca2+ release alkalized lysosomal pH in non-AD HiN, while no further pH changes occurred in AD HiN. Ryanodex treatment (10μM; 1h) attenuated the RyR-mediated lysosomal alkalization and restored baseline lysosomal pH in AD HiN. (I) Bafilomycin (25nM; 4h) alkalized lysosomal pH, and no additional pH changes occurred in response to RyR-evoked Ca2+ release in non-AD nor AD HiN. *P < 0.05CC BY-NC-ND · PubMed Central
Fig. 5. Normalizing RyR-Ca2+ release rescues disrupted proteolytic activity in HiN. (A) Representative images of lysosomal proteolytic activity, measured by DQTM-Red BSA, in HiN treated with control, Ryanodex and bafilomycin are shown. (B) Quantification of fluorescence intensity showed decreased protease activity in AD HiN, which was rescued with Ryanodex (10µM; 6h) treatment. vATPase inhibition with bafilomycin (25nM; 4h) demolished protease activity in both non-AD and AD HiN (n = 5 coverslips/treatment) *P < 0.05.
Fig. 5. Normalizing RyR-Ca2+ release rescues disrupted proteolytic activity in HiN. (A) Representative images of lysosomal proteolytic activity, measured by DQTM-Red BSA, in HiN treated with control, Ryanodex and bafilomycin are shown. (B) Quantification of fluorescence intensity showed decreased protease activity in AD HiN, which was rescued with Ryanodex (10µM; 6h) treatment. vATPase inhibition with bafilomycin (25nM; 4h) demolished protease activity in both non-AD and AD HiN (n = 5 coverslips/treatment) *P < 0.05.CC BY-NC-ND · PubMed Central
Fig. 6. Autophagic clearance of hyperphosphorylated tau is dependent on regulated RyR-Ca2+ signaling in mice. Hippocampus from 3–4-mo-old 3xTg-AD mice and age-matched NTg controls were immunolabled for autophagosomes (LC3B) and early-stage phosphorylated tau (S262). (A) Representative high-resolution images were taken on Leica SP8 63X with 441X zoom of the primary cellular layer (PCL) and stratum radiatum (SR) of the CA1 field. Quantification showed decreased fluorescence density of (B) LC3B and increased fluroesence density of(C) p-tau S262 in multiple regions of the hippocampus (CA1, CA3, DG) and cortex of 3xTg-AD mice, which was rescued with Ryanodex treatment (10mg/kg; 30-d i.p.). (NTg Vehicle, black bar, n = 8 animals; NTg Ryanodex, black pattern bar, n = 8 animals; 3xTg Vehicle, grey bar, n = 8 animals; 3xTg Ryanodex, grey pattern bar, n = 8 animals) *P <0.05.
Fig. 6. Autophagic clearance of hyperphosphorylated tau is dependent on regulated RyR-Ca2+ signaling in mice. Hippocampus from 3–4-mo-old 3xTg-AD mice and age-matched NTg controls were immunolabled for autophagosomes (LC3B) and early-stage phosphorylated tau (S262). (A) Representative high-resolution images were taken on Leica SP8 63X with 441X zoom of the primary cellular layer (PCL) and stratum radiatum (SR) of the CA1 field. Quantification showed decreased fluorescence density of (B) LC3B and increased fluroesence density of(C) p-tau S262 in multiple regions of the hippocampus (CA1, CA3, DG) and cortex of 3xTg-AD mice, which was rescued with Ryanodex treatment (10mg/kg; 30-d i.p.). (NTg Vehicle, black bar, n = 8 animals; NTg Ryanodex, black pattern bar, n = 8 animals; 3xTg Vehicle, grey bar, n = 8 animals; 3xTg Ryanodex, grey pattern bar, n = 8 animals) *P <0.05.CC BY-NC-ND · PubMed Central
Fig. 7. Regulated RyR-Ca2+ release is necessary for autophagy-mediated clearance of intracellular protein aggregates, like hyperphosphorylated tau. (A) Representative images of autophagic vesicles, measured by DAP-green autophagy detection dye in non-AD and AD HiN. (B) Quantification of fluorescence density of autophagic vesicles shows increased density of autophagic vesicles in AD HiN, which are rescued with Ryanodex treatment (10µM; 6h; n = 5 coverslips/treatment). (C) Representative images of fixed HiN cultures immunolabeled for hyperphosphorylated tau (AT8). (D) Quantification of fluorescence density of hyperphosphorylated tau shows increased AT8 in AD HiN. Inhibition of vATPase with bafilomycin (25nM; 4h) exacerbated p-tau in non-AD HiN. Ryanodex (10µM; 6h) treatment reduced the elevated AD-associated hyperphosphorylated tau in AD HiN. (n = 10 coverslips/treatment). (E–G) Aβ42- and Aβ40-specific ELISA of the supernatant from the non-AD and AD HiN showed increased secreted Aβ42/Aβ40 in AD neurons. (F) No difference was seen in Aβ40 levels across treatments. Bafilomycin treatment (25nM; 4h) did not exacerbate secreted Aβ42/Aβ40 levels in non-AD HiN, showing that blocking autophagy has a more profound effect on intracellular deposits than extracellular deposits. Additionally, Ryanodex (10µM; 6h) treatment significantly reduced extracellular Aβ42/Aβ40 levels in AD HiN comparable to non-AD HiN (n = 8 wells/treatment). *P <0.05.
Fig. 7. Regulated RyR-Ca2+ release is necessary for autophagy-mediated clearance of intracellular protein aggregates, like hyperphosphorylated tau. (A) Representative images of autophagic vesicles, measured by DAP-green autophagy detection dye in non-AD and AD HiN. (B) Quantification of fluorescence density of autophagic vesicles shows increased density of autophagic vesicles in AD HiN, which are rescued with Ryanodex treatment (10µM; 6h; n = 5 coverslips/treatment). (C) Representative images of fixed HiN cultures immunolabeled for hyperphosphorylated tau (AT8). (D) Quantification of fluorescence density of hyperphosphorylated tau shows increased AT8 in AD HiN. Inhibition of vATPase with bafilomycin (25nM; 4h) exacerbated p-tau in non-AD HiN. Ryanodex (10µM; 6h) treatment reduced the elevated AD-associated hyperphosphorylated tau in AD HiN. (n = 10 coverslips/treatment). (E–G) Aβ42- and Aβ40-specific ELISA of the supernatant from the non-AD and AD HiN showed increased secreted Aβ42/Aβ40 in AD neurons. (F) No difference was seen in Aβ40 levels across treatments. Bafilomycin treatment (25nM; 4h) did not exacerbate secreted Aβ42/Aβ40 levels in non-AD HiN, showing that blocking autophagy has a more profound effect on intracellular deposits than extracellular deposits. Additionally, Ryanodex (10µM; 6h) treatment significantly reduced extracellular Aβ42/Aβ40 levels in AD HiN comparable to non-AD HiN (n = 8 wells/treatment). *P <0.05.CC BY-NC-ND · PubMed Central
Fig. 8. Protein handling via lysosomal-autophagosome pathway is disrupted in early stages of Alzheimer’s disease. Dysregulated RyR-Ca2+ signaling leads to elevated cytosolic Ca2+ concentration. This rise of Ca2+ disrupts lysosomal vATPase proton pump, resulting in alkalization of the lysosomal lumen. The alkaline environment is not conducive for lysosomal protease, cathepsin, and hydrolase activity, thereby disrupting proteolysis of cellular debris. Autophagic clearance is halted, and turnover of bulky, misfolded proteins, and damaged organelles is disrupted. Intracellular aggregates such as hyperphosphorylated tau accumulate within autophagic vacuoles furthering AD proteinopathy.
Fig. 8. Protein handling via lysosomal-autophagosome pathway is disrupted in early stages of Alzheimer’s disease. Dysregulated RyR-Ca2+ signaling leads to elevated cytosolic Ca2+ concentration. This rise of Ca2+ disrupts lysosomal vATPase proton pump, resulting in alkalization of the lysosomal lumen. The alkaline environment is not conducive for lysosomal protease, cathepsin, and hydrolase activity, thereby disrupting proteolysis of cellular debris. Autophagic clearance is halted, and turnover of bulky, misfolded proteins, and damaged organelles is disrupted. Intracellular aggregates such as hyperphosphorylated tau accumulate within autophagic vacuoles furthering AD proteinopathy.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 98 references

Cited by

See all 55

Metadata

Authors
Mustaly-Kalimi, S., Gallegos, W., Marr, R. A., Gilman-Sachs, A., Peterson, D. A., Sekler, I., & Stutzmann, G. E.
Affiliations
  • Rosalind Franklin University of Medicine and Science (US)
  • Center for Cancer Cell Biology, Immunology and Infection, Rosalind Franklin University of Medicine and Science, Immunology, and Infection, North Chicago, IL 60064
  • Ben-Gurion University of the Negev (IL)
Corresponding author
Stutzmann, Grace E.
Venue
Proceedings of the National Academy of Sciences
Published
2022-11-28
Volume
119
Issue
49
Pages
e2211999119-e2211999119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4310102451
Cited by
55
References
97
Citations by year
2026: 13 · 2025: 16 · 2024: 18 · 2023: 8
FWCI
6.50
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
HHS | NIH | National Institute on Aging (AG065628)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
Alzheimer's disease, intracellular calcium dysregulation, ryanodine receptor, endoplasmic reticulum calcium release, lysosomal acidification, vacuolar ATPase, lysosomal proteolysis, autophagy, tau hyperphosphorylation, protein aggregates, dantrolene, iPSC-derived neurons, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Calcium, Calcium, Dietary, Dantrolene, Disease Models, Animal, Humans, Lysosomes, Ryanodine Receptor Calcium Release Channel, Mice, Proteolysis, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease. https://app.cochat.ai/papers/10.1073/pnas.2211999119
The paper
Mustaly-Kalimi, S., Gallegos, W., Marr, R. A., Gilman-Sachs, A., Peterson, D. A., Sekler, I., & Stutzmann, G. E. (2022). Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2211999119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.